Streetbeat News

LQDA

Liquidia Corporation

https://www.liquidia.com

Industry

Biotechnology

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. It also distributes generic treprostinil injection in the United States. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.

Open

10.12

Mkt cap

819M

Volume

943K

High

10.13

P/E Ratio

-6.23

52-wk high

16.99

Low

9.79

Div yield

N/A

52-wk low

6.19

LifeSci Capital has initiated coverage on Liquidia with an Outperform rating and set a price target of $30.

Portfolio Pulse from Benzinga Newsdesk

October 03, 2024 | 2:04 pm

Liquidia and Pharmosa Biopharm have amended their exclusive licensing agreement for the development and commercialization of sustained release inhaled Treprostinil. This amendment could impact Liquidia's business strategy and market position.

Portfolio Pulse from Benzinga Newsdesk

October 02, 2024 | 10:01 am

A court ruling found that United Therapeutics' interference with the launch of a generic Treprostinil Injection caused over $137M in losses. Liquidia Corporation, in partnership with Sandoz, was affected by this interference.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 1:43 pm

The Nasdaq Composite surged over 200 points, driven by a rise in information technology shares. PureCycle Technologies, BriaCell Therapeutics, and Liquidia Corporation saw significant stock price increases due to positive company announcements. Conversely, Telesis Bio, Rentokil Initial, and Torrid Holdings experienced sharp declines following negative news. U.S. crude oil inventories rose slightly less than expected.

Portfolio Pulse from Avi Kapoor

September 11, 2024 | 6:30 pm

Liquidia's stock price increased following the announcement of a $67.5 million capital raise through the sale of 6,460,674 common shares at $8.90 each.

Portfolio Pulse from Benzinga Newsdesk

September 11, 2024 | 2:36 pm

Several stocks saw significant gains on Wednesday despite a general market downturn. Petco Health and Wellness (WOOF) rose 8.4% despite reporting larger-than-expected losses. PureCycle Technologies (PCT) jumped 20% following a financing announcement. Sigma Lithium (SGML), Lithium Americas (LAAC), and Albemarle (ALB) gained due to a rise in lithium prices. Hyliion Holdings (HYLN) rose after securing a Navy contract. Dave & Buster’s (PLAY) increased after better-than-expected earnings. AppLovin (APP) gained following a price target increase by B of A Securities.

Portfolio Pulse from Avi Kapoor

September 11, 2024 | 2:19 pm

Liquidia Corporation (NASDAQ:LQDA) has announced a $67.5 million raise through a public offering and private placement of common stock, alongside a $32.5 million advance from HealthCare Royalty. The funds will support the development of YUTREPIA and other projects.

Portfolio Pulse from Benzinga Newsdesk

September 11, 2024 | 12:29 pm

HC Wainwright & Co. analyst Andrew Fein has reiterated a Buy rating for Liquidia (NASDAQ:LQDA) and maintained a price target of $29.

Portfolio Pulse from Benzinga Newsdesk

August 23, 2024 | 11:17 am

Needham analyst Serge Belanger has reiterated a Buy rating on Liquidia (NASDAQ:LQDA) and maintained a price target of $19.

Portfolio Pulse from Benzinga Newsdesk

August 22, 2024 | 4:02 pm

Liquidia has filed a lawsuit challenging the FDA's decision to grant 3-year exclusivity to Tyvaso DPI, delaying the final approval of its own drug, YUTREPIA, until May 2025.

Portfolio Pulse from Benzinga Newsdesk

August 22, 2024 | 10:05 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.